Abstract:Small therapeutic proteins are receiving increased interest as therapeutic drugs; however, their clinical success has been limited due to their rapid elimination. Here, we report a half-life extension strategy via strategy via red blood cell red blood cell (RBC) hitch-hiking. This manuscript details the development and characterization of novel anti-RBC single-domain antibodies (sdAbs), their genetic fusion to therapeutic antibody fragments (TAF) as bispecific fusion constructs, and their influence on TAF pharmacokinetics and biodistribution. Several sdAbs specific to the band 3 antigen were generated via phage-display technology. Binding affinity to RBCs was assessed via flow cytometry. Affinity maturation via random mutagenesis was carried out to improve the binding affinity of the sdAbs. Bi-specific constructs were generated by fusing the anti-RBC sdAbs with anti-tissue necrosis factor alpha (TNF-α) TAF via the use of a glycine-serine flexible linker, and assessments for binding were performed via enzyme-linked immunosorbent assay and flow cytometry. Pharmacokinetics of anti-RBC sdAbs and fusion constructs were evaluated following intravenous bolus dosing in mice at a 1 mg/kg dose. Two RBC-binding sdAbs, RB12 and RE8, were developed. These two clones showed high binding affinity to human RBC with an estimated KD of 17.7 nM and 23.6 nM and low binding affinity to mouse RBC with an estimated KD of 335 nM and 528 nM for RB12 and RE8, respectively. Two derivative sdAbs, RMA1, and RMC1, with higher affinities against mouse RBC, were generated via affinity maturation (KD of 66.9 nM and 30.3 nM, respectively). Pharmacokinetic investigations in mice demonstrated prolonged circulation half-life of an anti-RBC-TNF-α bispecific construct (75 h) compared to a non-RBC binding control (1.3 h). In summary, the developed anti-RBC sdAbs and fusion constructs have demonstrated high affinity in vitro, and sufficient half-life extension in vivo.

Engineered Antibody Domains With Significantly Increased Transcytosis And Half-Life In Macaques Mediated By Fcrn

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life

Engineered Antibody Variable And Constant Domains As Therapeutic Candidates

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria

Bispecific Engineered Antibody Domains (nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn.

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4

Trimming Crystallizable Fragment (fc) Glycans Enables the Direct Enzymatic Transfer of Biomacromolecules to Antibodies As Therapeutics.

Half-Life Extension and Biodistribution Modulation of Biotherapeutics via Red Blood Cell Hitch-Hiking with Novel Anti-Band 3 Single-Domain Antibodies

Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.

An Unexpected Single-step Glycosylation Enables the Construction of Antibody-Biomacromolecule Conjugates As Therapeutics

Single Chain Antibody Fragments with Ph Dependent Binding to FcRn Enabled Prolonged Circulation of Therapeutic Peptide in Vivo.

Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.

Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains.

Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0.

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance

An Antibody CDR3-erythropoietin Fusion Protein.

Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding

Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques

Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation

Single-step Enzymatic Glycoengineering for the Construction of Antibody-cell Conjugates